Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu (Q80417682)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15294176%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

title

Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15294176%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Chi-Chen Lin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15294176%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Ching-Wen Chou

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15294176%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Ai-Li Shiau

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15294176%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Cheng-Fen Tu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15294176%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Tai-Ming Ko

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15294176%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Yi-Ling Chen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15294176%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Bei-Chang Yang

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15294176%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Mi-Hua Tao

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15294176%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Ming-Derg Lai

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15294176%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

1 August 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15294176%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15294176%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15294176%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15294176%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

290-301

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15294176%20AND%20SRC:MED&resulttype=core&format=json

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

31 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

The neu oncogene encodes an epidermal growth factor receptor-related protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Cancer vaccines targeting the HER2/neu oncogenic protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Humanization of an anti-p185HER2 antibody for human cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Trastuzumab: hopes and realities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

ErbB2 is essential in the prevention of dilated cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

DNA vaccines: a key for inducing long-term cellular immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Genetic immunization against neu/erbB2 transgenic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Insertion of the DNA for the 163-171 peptide of IL1beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

DNA vaccination against neu reduces breast cancer incidence and metastasis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Efficacy of vaccination with plasmid DNA encoding for HER2/neu or HER2/neu-eGFP fusion protein against prostate cancer in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Regulation of tumor progression by anti-neoplastic T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Induction of a cellular and humoral immune response against preprocalcitonin by genetic i: a potential new treatment for medullary thyroid carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Radiofrequency destruction of the tuberoinfundibular region of hypothalamus permanently abrogates NK cell activity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Natural killer cells and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Relationship of anti-GM-CSF antibody concentration, surfactant protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Treatment-induced antibodies to interleukin-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

The inducible lactose operator-repressor system is functional in the whole animal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

The potential of DNA vaccination against tumor-associated antigens for antitumor therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2004.05.015

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YMTHE.2004.05.015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15294176%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference